Trial Profile
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Pharmacogenomic; Therapeutic Use
- 20 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 30 May 2023 Planned primary completion date changed from 30 Sep 2023 to 31 Dec 2023.
- 20 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Sep 2023.